3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow ENMD 2076: new trials by email Literature Review of ENMD 2076 trials Research Report on ENMD 2076
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies ENMD-2076 - Relapsed or Refractory Hematological Malignancies | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 27 | 2009-04-01 | 2011-08-04 |
| Study of ENMD-2076 in Patients With Multiple Myeloma ENMD-2076 - Multiple Myeloma | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 13 | 2008-12-01 | 2023-02-06 |
| A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer ENMD-2076 - Advanced Cancer | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 67 | 2008-04-01 | 2023-02-06 |
Hematologic Neoplasms (1) · Leukemia (1) · Multiple Myeloma (1) · Recurrence (1)
CASI pharmaceuticals, Inc. (3)
United States (2) · Canada (1)